Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003657 · ClinicalTrials.gov registry record · Phase 2
High-dose ICE With Amifostine
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00003657 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 24 participants.
The verdict
NCT00003657, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at conventional doses.
Interventions
- DRUG Carboplatin
- DRUG Etoposide
- DRUG Ifosfamide
- BIOLOGICAL filgrastim
- DRUG Amifostine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1998-07 |
| Est. Completion | 2002-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003657
The ClinicalTrials.gov registry entry for NCT00003657 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT00003657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003657 about?
NCT00003657 is a clinical study titled "High-dose ICE With Amifostine". The purpose of the study is to evaluate the combination of amifostine and high dose chemotherapy with blood stem cell support. Amifostine is a druf developed to protect normal tissues against the toxicities of chemotherapy and radiotherapy and has reduced the side effects of chemotherapy given at co...
What is the current status of trial NCT00003657?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 1998-07. Estimated completion is 2002-06.
What interventions are being tested in trial NCT00003657?
The interventions under investigation include: Carboplatin (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), filgrastim (BIOLOGICAL), Amifostine (DRUG).
Who is sponsoring clinical trial NCT00003657?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.